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A placebo-controlled trial comparing the efficacy
of indoramin with alpha-methyldopa
J. ANTHONY, A. E. REES, D. A. DAVEY
Summary
A placebo-controlled trial was used to assess the anti-
hypertensive efficacy of indoramin in the management of
pregnancy hypertension. Sixty patients were recruited into
the study and only 17 attained satisfactory blood pressure
control. In the doses of drugs administered indoramin was
not shown to be more effective than alpha-methyldopa.
S Atr Med J 1990; 78: 458-461.
The use of antihypertensive agents in pregnancy hypertension
is controversial, since treatment is primarily directed to the
control of one of the manifestations and not to the disease
itself. Severe hypertension, however, may be a risk to the
mother and necessitate treatment. When hypertension is severe
and thl' '"etus is immature it may be possible to 'buy time' with
antihypertensive therapy and allow the fetus to attain maturity
and be safely delivered. The choice of antihypertensive drug in .
pregnancy depends on the mechanism of action of the drug
used, its efficacy and its P9ssible effects of the fetus. The ideal
antihypertensive should reduce peripheral resistance but not
impair maternal cardiac output and should not reduce uterine
perfusion. If peripheral vasodilatation is disproportionately
greater than. the vasodilatation of the uterine vessels this may
reduce uterine blood flow and produce fetal hypoxia. An ideal
agent should not only lower blood pressure but should also
preferentially vasodilate the uterine circulation and increase
uterine blood flow.
The number of placebo-controlled clinical trials has been
relatively few l- 6 and the ability of many antihypertensive
agents to produce a sustained fall of blood pressure, particularly
in severe hypertension, remains to be demonstrated. Further-
more, many drugs have been used in the treatment of preg-
nancy· hypertension but none have been shown to improve
choriodecidual perfusion and fetal benefits have been marginal.
Some antihypertensive drugs have significant side-effects on
the mother or produce deleterious effects on the fetus, which
may limit their use.
Indoramin is a selective ai-postsynaptic adrenergic antago-
nist with membrane-stabilising properties, and it has been
shown to be of value in the treatment of non-pregnant hyper-
tensive patients. It produces vasodilatation without impairing
cardiac outpue,8 and theoretically, is a potentially good drug
for the treatment of hypertension in pregnancy. A randomised
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controlled clinical trial was carried out to compare the effects
of indoramin with those of an established antihypertensive
drug, alpha-methyldopa, and those of a placebo.
Patients and methods
Black and coloured patients between 28 weeks' and 36 weeks'
gestation attending the Pregnancy Hypertension Clinic at
Groote Schuur Hospital were recruited into the study after
informed consent about the nature and purpose of the trial
had been obtained. All patients were admitted for preliminary
assessment and were only entered into the trial if their mean
24-hour diastolic blood pressure after admission was in the
range 100 - 120 mmHg with or without proteinuria.
Patients were allocated to one of three treatment groups
(indoramin, methyldopa or placebo) using. a randomised block
design in which the patients were divided into 1 of 4 patient
categories: primigravid or multigravid, and proteinuric or non-
proteinuric. This design was used to reduce the .possible
confounding effect of difference in the nature and the severity
of the underlying disease on the response to treatment. The
trial was conducted in three phases.
Phase I
Patients were randomly allocated to indoramin 50 mg twice
daily or alpha-methyldopa 1 g twice daily or placebo 1 tablet
daily. The patients remained in hospital for 5 days and 6-
hourly blood pressure observations, daily urinary protein quan-
titation, twice-weekly full blood counts and tests of renal and
liver function were performed. All blood pressure measure-
ments were made by sphygmomanometry with the patient at
rest on her side using an appropriate size cuff and the 4th
Korotkoff sound to derme the diastolic blood pressure. Each
patient was asked daily about any symptoms; these were
noted. The condition of the fetuses was monitored by ultra-
sonography fortnightly, by non-stress cardiotocography twice
weekly and, where indicated, by acoustic stimulation testing.
At the end of phase. I the patients' blood pressures were
considered to be controlled if the mean 24--hour diastolic blood
pressure on day 5 was 90 mmHg or less. Patients whose blood
pressures were successfully controlled in phase I were dis-
charged from the hospital for follow-up -in the Pregnancy
Hypertension Clinic and entered into phase III of the trial.
PhaseD
Patients who completed phase I of the trial but in whom
satisfactory blood pressure was not achieved (diastolic blood
pressure ~ 90 mmHg) were entered into· phase II of the trial.
In this phase all the patients were treated with a cOmbination
of alpha-methyldopa 1 g twice daily and indoramin 50 mg
twice daily regardless of their initial treatment. The same
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TABLE I. DIAGNOSTIC CATEGORY AND
PHASE ONE RECRUITMENT
Category Methyldopa Indoramin Placebo Total
Primigravid non-proteinuric 3 3 2 8
Multigravid non-proteinuric 8' 8 8 24
Primigravid proteinuric 3 4 4 11
Multigravid proteinuric 6 5 6 17
maternal and fetal observations were performed as in phase I
of the trial and continued for funher 5 days. Patients whose
blood pressures were satisfactorily controlled (diastolic blood
pressure ~ 90 mmHg) were entered into phase III of the trial
and discharged for follow-up. Patients whose blood pressure
were not controlled at the end of phase 11 were regarded as
treatment failures and withdrawn from the trial.
Phase ill
Those patients successfully treated in phases I and 11 were
discharged for outpatient follow-up. During this phase the
continuing efficacy of the treatment and patient compliance
during the remainder of the pregnancy was assessed.
Withdrawals
Patients were withdrawn from the trial in any phase if they
developed significant deterioration in the maternal condition
(increasing .,roteinuria and/or decreasing renal function) or
any signs OI unpaired fetal well-being irrespective of the blood
pressure level. Non-eompliant patients were also withdrawn.
These patients were all categorised as 'withdrawals'. Those
patients who required additional antihypenensive treatment
because of severe hypenension (diastolic blood pressure ~ 120
mmHg) or failure to control the blood pressure at the end of
phase 11 or during phase III were categorised as treatment
failures.
Statistics
The mean anerj.al pressures (MAP) were analysed by one-
way analysis of variance and numbers of patients controlled in
each group by Fisher's exact test.
Results
A total of 60 patients were recruited into the trial and their
distribution according to parity and the presence or absence of
proteinuria is shown in Table I. The largest group comprised
non-proteinuric multiparous patients. Equal numbers of
patients were allocated to treatment with alpha-methyldopa,
indoramin and placebo within patient groups according to a
randomised block design.
Demographic data and baseline renal function are shown in
Tables 11 and Ill.
TABLE 11. DEMOGRAPHIC DATA (MEAN ± SO)
Gestational age Maternal age
Category at recruitment (wks) (yrs)
Non-proteinuric primigravida 31,8 ± 1,9 23 ± 8
Proteinuric primigravida 29,9 ± 2,3 23 ± 6
Non-proteinuric multiparous 31,7 ± 2,4 31 ± 8
Proteinuric multiparous 30,5 ± 2,3 29 ± 6
Phase I - non-proteinuric patients (Table IV)
The blood pressure was controlled in a significant proportion
of non-proteinuric multiparous patients but there were no
significant differences between the proportion of patients con-
trolled by alpha-methyldopa, indoramin or placebo. The fall in
MAP in the methyldopa group was, however, significantly
greater than in the placebo group. The fall in MAP in the
indoramin group was not significantly different from that in
the placebo group. In the non-proteinuric primigravid patients
the alpha-methyldopa group had the greatest fall in MAP but
this was not statistically significantly greater than placebo.
None of these patients achieved satisfactory blood pressure
control regardless of the treatment administered.
Phase I - proteinuric patients (Table V)
Among the proteinuric multiparous patients neither alpha-
methyldopa nor indoramin showed any statistically significant
advantage over placebo either in the reduction of average
MAP or the numbers of patients controlled. The proteinuric
primigravid patients similarly showed no fall in blood pressure.
Phase IT (Table VI)
In the second phase of the trial 32 out of the original 60
patients sraned combined treatment with indoramin and alpha-
methyldopa. In this phase the blood pressure was controlled in






TABLE Ill. BASEUNE RENAL FUNCTION (MEAN ± SO)
Serum urea Serum creatinine Serum urate
. (JLmol/l) (Jlmol/l) (JLmol/l)
2,7 ± 1,1 63,1 ± 16,7 0,31 ± 0,13
3,5 ± 0,7 68,4 ± 11,1 0,36 ± 0,06
2,7 ± 0,7 61,7 ± 9,6 0,29 ± 0,06
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TABLE IV. NON-PROTEINURIC PATIENTS, OUTCOME TABLE VII. OUTCOME PHASE I AND 11 COMBINED




M P M P M P Controlled 9" 1
No. recruited 8 3 8 3 8 2 Single agent Withdrawn 6 3
No. controlled 4 0 3 0 2 0 Failure 3 6
Withdrawal 2 2 1 0 1 0 Combination
l
Entered 14 18
Failures 2 0 1 0 0 0 methyldopa Controlled 5 2
Mean change in MAP plus indoramin Withdrawn 3 6
(mmHg) -17" -14,7 -7,8 -2,7 1,1 -2,5 Failure 6 10
'Indicates statistically significant difference compared with placebo. Total controlled 14" 3
M = multigravid; P = primigravid.
-Indicates statistical significance.
M =multigravid; P =primigravid.
18 proteinuric patients. Analysis of phases I and 11 (Table
VII) combining all treatments showed that the blood pressure
was controlled in a statistically significantly greater percentage
of the non-proteinuric group of patients in comparison with
the proteinuric group.
Phase ill
Only 17 patients were discharged on treatment for follow-
up in phase III of the trial and only 7 of these (all non-
proteinuric) remained satisfactorily controlled on the trial
drugs.
Withdrawals
An analysis of the patients withdrawn showed that there
were no significant differences between the methyldopa,
indoramin and placebo group in phase I and that the overall
indication for withdrawal was almost equally divided between
fetal and maternal indications. None of the withdrawals were
due to side-effects during treatment.
Discussion
Indoramin is an O!I-postsynaptic adrenergic antagonist that
reduces bloo.d pressure through peripheral vasodilatation.
Important pharmacological properties of the drug include the
selectivity of its action on the 0!2-poStSynaptic receptors as well
as its membrane-stabilising properties, both of which contribute
to the absence of tachycardia, which characterises other O!-
adrenergic receptor blockers.9
The drug was initially found to be of benefit in the treatment
of non-pregnant patients with hypertension and a co-existing
medical problem (such as obstructive airways disease) that
would contraindicate the use of a ,B-blocker.
An uncontrolled study in 21 patients with a contraindication
to ,B-blocker therapy showed a 90% satisfactory respunse rate
when indoramin was combined with diuretic therapy.IO The
use of the drug in the treatment of mild-to-moderate essential
hypertension was studied in a double-blind cross-over study
comparing the efficacy of indoramin with alpha-methyldopa.
This study revealed that both drugs produced satisfactory
control of blood pressure and that no differences existed with
regard to the incidence of side-effects. 11
In 1981 the results of 7 long-term clinical trials involving
the use of indoramin for the treatment of essential hyper-
tension were analysed and 60% of the patients treated were
found to have had an 'excellent' response, 25% a 'good'
response and only 15% a 'poor' response.12
The acute and chronic cardiovascular effects of indoramin
and prazosin have been compared in normal man and the 'first
dose' syncopal effect of prazosin was found to be absent with
indoramin. This was attributed to the greater venodilating
effects of prazosin compared with indoramin. 13 The lack of an
ideal antihypertensive agent in the treatment of pregnancy
hypertension and the successful use of indoramin in the
treatment of hypertension in non-pregnant subjects suggested
that a clinical trial of indoramin in hypertension of pregnancy
would be of value, particularly in view of its action as an O!l-



































TABLE VI. OUTCOME OF THERAPY WITH METHYLDOPA AND INDORAMIN, PHASE 11
Primigravid Multiparous Primigravid Multiparous
non-proteinuric non-proteinuric proteinuric proteinuric
6 8 8 10
3 2 1 1
2 1 1 5
156 4
In our trial the patients were grouped on the basis of parity
md the presence of proteinuria, since the hypenensive dis-
lrders of pregnancy are probably not one entity but a number
lf different disorders. The trial showed that the use of anti-
ilypenensive drugs in the doses specified on the population
;tudied is, for the most pan, unsuccessful and that this is
larticularly so in the case of patients who not only have
lypenension but proteinuria as well. The non-proteinuric
nultiparous patients who responded to treatment were almOSt
:enainly latent or chronic essential hypenensive subjects.
Indoramin did not produce a statistically significant reduc-
ion in MAP compared with placebo, whereas alpha-methyl-
iopa did so in at least one group of patients. The relative
:ailure of methyldopa in this trial compared with the results of
>ther trials may be due to methodological differences; the
)xford group restricted their study to the treatment of non-
>roteinuric patients and employed different criteria to establish
he antihypenensive efficacy of the drug. I'
Neither indoramin nor methyldopa was associated with any
:ide-effects in the dosages used. In particular, none of the
>atients on alpha-methyldopa complained of drowsiness in
pite of this being a well-reponed side-effecr of this drug.
\nalysis of the 'withdrawals' showed that all were due to
leterioration in the condition of the mother or the fetus and
lrogression of the underlying disease.
Indoramin and alpha-methyldopa would appear to have a
imited role to play in the management of patients with
Iypenension in pregnancy. The combination of methyldopa
nd indoramin, however, may increase the number of patients
~ho attain satisfactory blood pressure control, particularly
~here single-agent therapy has failed. In the dosages used,
'oth indoramin and methyldopa only produced satisfactory
ontrol in about 50% of patients and this was almost entirely
onImed to non-proteinuric patients and even then the dura-
ion of effectiveness was limited. The use of indoramin and
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a-adrenergic antagonists as single agents in the treatment of
hypenension in pregnancy appears to be limited.
The authors wish to thank Sister P. Stewarr for her untiring
entl(usiasm and Mr S. Isaacs for the statistical analysis.
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